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OBJECTIVES To investigate primary angioplasty (PA) for high-risk acute myocardial infarction (AMI) at
hospitals with no cardiac surgery on-site (No SOS), we hypothesized that a nonrandomized
registry of such patients treated with PA would show clinical outcomes similar to those of a
group randomized to transfer for PA, and that reperfusion would occur faster.
BACKGROUND Primary angioplasty provides outcomes superior to fibrinolytic therapy in AMI, but its use in
community hospitals with No SOS has been limited.
METHODS Fibrinolytic-eligible patients with high-risk AMI prospectively consented if they had one or
more high-risk characteristic. Nineteen hospitals with No SOS prospectively enrolled 500
patients for PA on-site. Seventy-one similar Air Primary Angioplasty in Myocardial
Infarction trial patients were randomized to transfer for PA.
RESULTS Primary angioplasty was performed in 88% of patients. Patients transferred for PA had a
longer mean time to treatment (187 vs. 120 min; p  0.0001). Thrombolysis In Myocardial
Infarction (TIMI) flow grade 3 was achieved in 96% for on-site PA, 86% in the transfer group
(p  0.004). The combined primary end point of 30-day mortality, re-infarction, and
disabling stroke occurred in 27 (5%) on-site PA patients and 6 (8.5%) transfer patients (p 
0.27). Unadjusted one-year mortality was improved in on-site PA patients compared with
those transferred (6% vs. 13%, p  0.043), but after adjustment for differences in baseline
variables, this difference was not significant.
CONCLUSIONS On-site PA and transfer groups had similar 30-day outcomes and more rapid reperfusion for
on-site PA. Primary angioplasty in high-risk AMI patients at hospitals with No SOS is safe,
effective, and faster than PA after transfer to a surgical facility. (J Am Coll Cardiol 2004;
43:1943–50) © 2004 by the American College of Cardiology Foundationa
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che superiority of primary angioplasty (PA) over fibrino-
ytic therapy for the treatment of acute myocardial infarction
AMI) in lytic-eligible patients has been firmly established
1,2). Compared with fibrinolytic therapy, PA has been
See page 1951
emonstrated to reduce the rates of death, stroke, recurrent
schemia, and re-infarction.
From the *Division of Cardiology, Exeter Hospital, Exeter, New Hampshire;
Department of Cardiology, William Beaumont Hospital, Royal Oak, Michigan;
Doylestown Hospital, Doylestown, Pennsylvania; §Hilton Head Hospital, Hilton
ead, South Carolina; Blount Memorial Hospital, Maryville, Tennessee; ¶Leesburg
egional Medical Center, Leesburg, Florida; #St. Joseph Community Hospital,
ishawaka, Indiana; **Auburn Regional Medical Center, Auburn, Washington;
†Piedmont Medical Center, Rock Hill, South Carolina; and ‡‡Mercy Medical
enter, Cedar Rapids, Iowa.
Manuscript received August 14, 2003; revised manuscript received October 21,t003, accepted October 28, 2003.Certain clinical features of fibrinolytic therapy have been
ssociated with very high morbidity and mortality. Among
hese are advanced age, anterior infarction, elevated heart
ate, lower blood pressure, or higher Killip classes. There-
ore, many physicians have selected a more aggressive
pproach for the management of patients with high-risk
linical features. Some physicians opt to transfer such
atients to an interventional center, with or without previ-
us administration of fibrinolytic therapy, despite the atten-
ant risk and delay of transfer, which prolongs times to
eperfusion (3) and thus could increase mortality (4). How-
ver, a recent meta-analysis of six trials of transfer for PA
ersus local thrombolysis demonstrated the superiority of
A, even in patients requiring transfer to an angioplasty
enter (5).
The frequent need to transfer high-risk patients early in
he course of AMI underscores the need to extend the
a
i
g
M
M
w
h
(
s
f
c
p
A
o
f
s
a
i
m
o
t
d
s
a
c
w
M
o
s
e
d
t
I
h
t
t
t
w
M
P
c
m
o
T
e
t
u
b
b
d
(
e
w
t
o
m
r
b
d
p
r
T
D
i
t
fi
s
r
l
a
c
g
w
P
b
t
t
r
o
L
u
f
m
e
i
a
m
r
t
1944 Wharton Jr. et al. JACC Vol. 43, No. 11, 2004
The PAMI-No SOS Study June 2, 2004:1943–50vailability of PA to more hospitals. One limitation of PA
s the often-accepted requirement for on-site cardiac sur-
ery. Only 39% of hospitals in the National Registry of
yocardial Infarction (NRMI) provide cardiac surgery (6).
ost patients with AMI present to community hospitals
ithout surgical programs, yet approximately 1,000 of these
ospitals have diagnostic cardiac catheterization laboratories
7). It is not unusual for these diagnostic laboratories to be
taffed by experienced interventionalists who routinely per-
orm intervention at surgical centers.
An emerging practice in some U.S. hospitals that have
atheterization laboratories but not cardiac surgery is to
erform PA on-site as the routine first-line treatment for
MI. The success of these programs is multifactorial, based
n having experienced interventionalists who routinely per-
orm elective angioplasty at tertiary centers, an experienced
taff, a well-equipped laboratory, and established protocols
nd agreements for emergent transfer to surgical centers (8).
Thus, hospitals with catheterization laboratories without
n-house cardiac surgery have another option in the treat-
ent of high-risk patients with AMI beyond administration
f fibrinolytics or immediate transfer to a tertiary center:
hese hospitals could invest the effort and resources to
evelop PA programs locally. If such programs were found
afe and effective, it could be clinically (and economically)
dvantageous to treat AMI patients on-site.
Several PA registries from hospitals without on-site
ardiac surgery have reported excellent outcomes, which
ere not compromised by a lack of surgical facilities (8–13).
ost of these are single-center registries that reported their
wn outcomes.
Multicenter studies of PA at hospitals without cardiac
urgery are needed to help assess the feasibility, safety, and
fficacy of this approach on a large scale. Accordingly, we
esigned the No Surgery On-Site (No SOS) registry arm of
he randomized Air Primary Angioplasty in Myocardial
nfarction (Air PAMI) study (14) to address this issue. We
ypothesized that high-risk fibrinolytic-eligible patients
reated on-site with PA will show clinical outcomes similar
o those of the group that was transferred (Air PAMI
ransfer arm) for acute intervention, and that reperfusion
Abbreviations and Acronyms
AMI  acute myocardial infarction
EC  emergency center
ECG  electrocardiographic
No SOS  No cardiac Surgery On-Site study
NRMI  National Registry of Myocardial Infarction
PA  primary angioplasty
PAMI  Primary Angioplasty in Myocardial Infarction
trial
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarctionill occur more quickly. (ETHODS
atient selection. Patients were considered if they had a
linical diagnosis of AMI: clinical symptoms lasting over 30
in and 12 h with electrocardiographic (ECG) evidence
f ST-segment elevation or new left bundle branch block.
o be included, patients were required to be fibrinolytic-
ligible (except that age was not used as a qualification) and
o have at least one high-risk qualifier: age over 70 years (no
pper age limit), anterior MI, ECG demonstrating left
undle branch block, heart rate over 100 beats/min, systolic
lood pressure 100 mm Hg in the absence of volume
epletion, or Killip class 2 or 3 congestive heart failure
including the presence of rales, S3 gallop, or pulmonary
dema).
Patients were excluded from study participation if they
ere ineligible for fibrinolytic therapy (history of stroke or
ransient cerebral event in the last 6 months, major surgery
r active gastrointestinal bleeding within the previous 2
onths, organ biopsy within 2 weeks, cardiopulmonary
esuscitation lasting 10 min or resulting in rib fracture,
lood pressure 200 mm Hg systolic or 110 mm Hg
iastolic), had cardiogenic shock (defined as systolic blood
ressure 80 mm Hg in the absence of bradycardia or
equiring vasopressors), or had a life-expectancy of 1 year.
he study was conducted according to the principles of the
eclaration of Helsinki, and all patients gave written,
nformed consent.
Eligible Air PAMI high-risk patients were randomized
o receive either emergent transfer for PA or on-site
brinolytic therapy. Eligible high-risk patients who pre-
ented to No SOS sites were prospectively enrolled in the
egistry arm of the study. The protocol recommended
ow-flow nasal oxygen, nitroglycerin, 325 mg oral aspirin,
nd intravenous beta-blockers. Anti-arrhythmics and cal-
ium blockers were not routinely administered. Heparin was
iven according to the treatment arm to which the patient
as assigned.
A procedure. As soon as possible after enrollment, a
olus of intravenous heparin was administered, but a con-
inuous infusion was not recommended. Patients were taken
o the cardiac catheterization laboratory. Coronary angiog-
aphy and left ventriculography were performed using low-
smolar ionic contrast medium (ioxaglate, Mallinckrodt, St.
ouis, Missouri). Coronary intervention was performed
nless the following exclusions precluded angioplasty: in-
arct vessel stenosis 70%, infarct vessel supplying so little
yocardium that the angioplasty risk outweighed the ben-
fit, unprotected left main stenosis60%, or disease requir-
ng coronary artery bypass graft surgery. The goal of
ngioplasty was restoration of normal coronary flow with
inimal residual stenosis. Stenting was encouraged for
esidual lesions 30% or the presence of a coronary dissec-
ion. An activated clotting time of 350 s was maintained
200 to 250 s if platelet glycoprotein IIb/IIIa inhibitors were
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June 2, 2004:1943–50 The PAMI-No SOS Studysed), and administration of fibrinolytic agents was
iscouraged.
o SOS registry site selection. We required the follow-
ng: experienced interventionalists who regularly do elective
ntervention at a surgical center, an experienced catheter-
zation team on a 24-h, 7-day per week call schedule, a
ell-equipped catheterization laboratory with digital imag-
ng equipment, a full array of interventional equipment,
ntra-aortic balloon pump capability, formalized written
rotocols to be in place for immediate transfer to a surgical
enter, and rigorous and ongoing quality assurance and
utcomes monitoring. We further required PA to be per-
ormed routinely as the first-line treatment of choice around
he clock by the investigator’s group. Nineteen sites were
elected for the No SOS registry. Forty-nine percent of the
o SOS registry patients were enrolled at sites just starting
p new PA programs conforming to these standards.
hirteen other sites participated in the randomized Air
AMI portion of the study.
linical end points. The primary end point of major
dverse cardiovascular events was the combined occurrence
f death, non-fatal re-infarction, or disabling stroke by 30
ays. Re-infarction was defined as recurrent ischemic symp-
oms in association with re-elevation of creatine phosphoki-
ase to three times the upper limit of normal. Disabling
troke was defined as neurologic deficits significantly affect-
ng activities of daily life. Ischemia was defined as persistent
schemic chest pain after reperfusion therapy or recurrent
ymptoms with ST-segment changes, new heart failure,
urmur, or creatine phosphokinase re-elevation.
ata collection. Clinical data were collected and detailed
ase-report forms completed at each hospital by a desig-
able 1. Baseline Characteristics of the Air PAMI-No SOS
opulation
Variables
Transfer for PA
(n  71)
On-Site PA
(n  499)
p
Valu
ge (yrs) 62 12 64 12 0.50
ender (%male) 76 71 0.35
ypertension (%) 51 51 0.99
istory of peripheral vascular
disease (%)
10 10 0.99
revious MI (%) 13 15 0.58
revious CABG (%) 3 6 0.57
iabetes (%) 23 19 0.51
igh-risk qualifiers (%)
Age 70 yrs 27 36 0.14
Heart rate 100 beats/min 37 34 0.66
SBP 100 mm Hg 38 44 0.31
Killip class 1 35 28 0.21
Anterior MI 77 52 0.000
LBBB on ECG 4 3 0.46
Two or more qualifiers 63 60 0.66
Three or more qualifiers 34 25 0.10
ata are presented as the median value  SD or percentage of patients.
AMI  acute myocardial infarction; CABG  coronary artery bypass grafting;
CG  electrocardiogram; LBBB  left bundle branch block; MI  myocardial
nfarction; No SOS  No cardiac Surgery On-Site study; PA  primary angioplasty;
AMI  Primary Angioplasty in Myocardial Infarction trial; SBP  systolic bloodcressure.ated clinical research coordinator. Physician investigators
nd coordinators were all volunteers; there was no compen-
ation through research or industry grants or contracts.
ase-report forms were sent to the PAMI Coordinating
enter at William Beaumont Hospital for data entry and
nalysis. The core laboratory at William Beaumont Hospital
eviewed all cineangiograms. One-month, six-month, and
ne-year follow-up data were obtained by telephone
ontact.
Monitoring of the case-report forms and hospital records
as performed by the PAMI Coordinating Center. All
rimary end points, as well as a random sampling of 20% of
atients, were reviewed by the clinical events committee,
hich was blinded to the treatment received.
tatistical analyses. Categorical variables, including end
oints of death, re-infarction, disabling stroke, and the
ombined primary end point of major adverse cardiovascular
vents, were examined using the chi-square test, as appro-
riate (expected frequencies 5); otherwise, the Fisher
xact test was used. Continuous variables were examined
sing the Wilcoxon rank-sum test, because some of the
ariables were not normally distributed. The primary end
oint of this study was death, re-infarction, or disabling
troke by 30 days. A step-down logistic regression analysis
as completed for one-year mortality, including indepen-
ent variables with a value p  0.15. A history of MI,
iabetes, time to treatment, and randomization to transfer
ere included regardless of the p value. All analyses were
ompleted using SAS version 8.0 (SAS Institute, Cary,
orth Carolina).
ESULTS
emographic variables and high-risk characteristics.
igh-risk AMI patients were enrolled from August 1996 to
arch 1999. During this time period, 71 patients in the Air
AMI study were randomized to transfer for PA, whereas
00 patients were enrolled in the No SOS registry from
ugust 1996 to June 1998. The demographic characteristics
nd high-risk enrollment criteria of the transfer and registry
roups are outlined in Table 1. Anterior MI was more
ommon in transfer compared with registry patients (77%
s. 52%; p  0.0001).
imes to reperfusion in patients receiving on-site PA.
or on-site PA, the median time from chest pain onset to
mergency center (EC) arrival was 87 min; from EC arrival
o first angiogram, 81 min; and from EC arrival to first
alloon inflation, 105 min. The median time from pain
nset to reperfusion was 201 min (Table 2).
reatments and time delays in transfer patients. All of
he 71 patients randomized to transfer were transferred
79% by ambulance and 21% by helicopter). No patient died
r required cardiopulmonary resuscitation during transfer.
inor events during transfer were observed in only three
atients (two patients with hypotension and one with
onfusion).
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The PAMI-No SOS Study June 2, 2004:1943–50Patients transferred for PA had longer median and mean
imes to treatment from first EC arrival to first balloon
nflation (mean 187 vs. 120 min, p  0.0001; median 166
s. 105 min, p  0.0001), which was due to the time
nvolved in their transfer and starting the invasive procedure
Table 2). Thus, there was a mean delay in treatment of 67
in for the transfer group.
reatments received. Among the transfer group, 100%
nderwent catheterization and 87% had PA; and among the
n-site PA group, 100% underwent catheterization and
8% had PA (Table 3). Eight patients randomized to
ransfer did not receive PA; two patients were treated
edically and six patients were referred for bypass surgery.
ngiotensin-converting enzyme inhibitors were used more
requently in the transfer group (68% vs. 54%, p  0.034).
owever, beta-blockers, abciximab, and stents were used
ore frequently in the on-site PA group (81% vs. 51%, p 
.0001; 41% vs. 20%, p  0.0005; and 53% vs. 34%, p 
.003, respectively).
Multivessel disease and ejection fraction were similar
etween the groups (Table 4). However, angiographic data
ndicate improved outcomes for on-site PA (final Throm-
olysis In Myocardial Infarction (TIMI) flow grade 3: 96%
s. 86%, p  0.004; final stenosis: 9% vs. 18%, p  0.001).
omplications. Table 5 lists the incidence of in-hospital
omplications. In the on-site PA group, only two patients
0.4%) were transferred for surgery due to failed PA;
able 2. Time to Treatment in the Air PAMI-No SOS Study
Time Intervals (min)
Transfer for PA
Median
(25th, 75th) Mea
hest pain onset to emergency
center arrival
90 (45, 170) 140
mergency center arrival to
angiography
155 (119, 194) 174
mergency center arrival to
balloon inflation
166 (131, 240) 187
hest pain onset to reperfusion
(balloon inflation)
270 (202, 362) 311
bbreviations as in Table 1.
able 3. Treatments Received in the Air PAMI-No SOS Study
Transfer for PA On-Site PA p Value
V lytics 1 (1.4%) 28 (5.6%) 0.24
atheterization 71 (100%) 499 (100%) 1.00
evascularization 68 (96%) 473 (95%) 1.00
A 62 (87%) 440 (88%) 0.89
ABG 10 (14%) 51 (10%) 0.32
spirin 68 (96%) 484 (97%) 0.46
CE inhibitors 48 (68%) 270 (54%) 0.034
eta-blockers 36 (51%) 405 (81%) 0.0001
igoxin 9 (12.7%) 83 (16.7%) 0.39
bciximab 14 (20%) 205 (41%) 0.0005
tent(s) 24 (34%) 263 (53%) 0.0029
ata presented are number (%) of patients.
ACE  angiotensin-converting enzyme; IV  intravenous; other abbreviations aspn Table 1.nother 5% were transferred for emergency surgery because
f critical coronary anatomy discovered on the triage angio-
ram. Of the transfer group, 5.6% underwent emergency
urgery; none of these were transferred for failed PA.
welve percent of the on-site PA group and 8% of the
ransfer group experienced bleeding requiring transfusion.
here were no significant differences in complications
etween the groups.
linical outcomes. On-site PA patients had a shorter
ength of hospital stay (5.2  4.0 days vs. 6.1  4.3 days, p
0.10) (Fig. 1). At 30 days, 8.5% of patients randomized
o transfer reached the primary end point of death, nonfatal
e-infarction, or disabling stroke, as compared with 5.0% in
he on-site PA group, (38% reduction, p  0.27). There
ere no significant differences in 30-day outcomes between
he groups, although there was a strong trend toward lower
0-day mortality in the on-site PA group (8.5% vs. 3.4%, p
0.054).
Unadjusted mortality at one year was significantly higher
or the transfer group versus on-site PA group (13% vs. 6%,
 0.043), but after adjustment for differences in baseline
ariables, this difference was not significant. There were no
ignificant differences at one year for the remaining out-
omes (re-infarction: 3% vs. 2.6%, p  0.67; disabling
troke: 0% vs. 2%, p  0.61; and combined end point: 14%
s. 9%, p  0.19) for the transfer versus on-site PA group.
A step-down multivariate logistic regression indicates
hat heart rate 100 beats/min, hypertension, chronic
bstructive pulmonary disease, Killip class1, no stent, and
nitial thrombus are significant predictors of mortality at one
ear (Table 6). Randomization to transfer for PA was not a
redictor of mortality (p  0.86).
ISCUSSION
rimary angioplasty is superior to fibrinolytic therapy for the
reatment of patients with AMI and is potentially applicable
o a much broader spectrum of patients with AMI. Only
ne in three patients with AMI is eligible to receive
brinolytics, and only one in four actually receives it (15).
atients in whom fibrinolytic therapy is inappropriate have
etter outcomes with PA (16–18). Yet in 1999, only 16% of
On-Site PA
p ValueD
Median
(25th, 75th) Mean  SD
6 87 (45, 167) 146  162 0.77
81 (60, 115) 107  127 0.0001
105 (80, 139) 120  69 0.0001
6 201 (148, 326) 261  171 0.017n  S
 14
 81
 75
 14atients with ST-segment elevation AMI in the NRMI-3
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June 2, 2004:1943–50 The PAMI-No SOS Studyatabase were treated with PA (19). This is partly due to the
act that most patients with AMI do not present to
ngioplasty centers.
There is a growing need to provide increased access to
A. Many recent trials have demonstrated the superiority of
A after transfer over on-site thrombolytic therapy for
atients with AMI presenting to hospitals that do not
rovide percutaneous coronary intervention (PCI)
5,14,20,21). Because most patients with AMI present to
ommunity hospitals and most community hospitals neither
an nor should be expected to provide on-site PA, systems
re essential to ensure the rapid and routine transfer or
rehospital ambulance triage of such patients to angioplasty
enters capable of emergency intervention on a 24-h, 7-day
er week basis.
The routine emergent transfer of patients with AMI,
owever, presents many difficulties (22). In the NRMI-2
nd -3 registries, transfer for PA in the U.S. was associated
ith a median delay in time to reperfusion of 90 min,
ompared with on-site PA (195 vs. 105 min, p 0.001) (3).
n these registries, patients who were treated after 150 min
ad a 60% increase in mortality, compared with patients
reated within 60 min (p  0.001) (4). In view of the risk
nd delay of transfer, physicians at many community hos-
able 4. Angiographic Data
Transfer for PA On-Site PA p Value
ultivessel disease 44 (62%) 280 (56%) 0.35
jection fraction 47 12 48 13 0.47
jection fraction 40% 28% 24% 0.52
inal
TIMI flow grade 3 86% 96% 0.004
Percent stenosis 18 22 9 14 0.0012
Dissection 16% 9% 0.09
Thrombus 3.2% 4.1% 1.00
nitial
TIMI flow grade 3 12.7% 13.8% 1.00
Percent stenosis 97 8 97 9 0.62
Dissection 13% 13% 0.86
Thrombus 67% 75% 0.19
ata are presented as the median value  SD or number (%) of patients.
PA  primary angioplasty; TIMI  Thrombolysis In Myocardial Infarction.
able 5. In-Hospital Complications
Complication Transfer for PA On-Site PA p Value
systole or heart block
requiring pacemaker
2 (2.8%) 29 (5.8%) 0.41
entricular fibrillation
(or tachycardia)
3 (4.2%) 25 (5%) 1.00
ulmonary edema 7 (9.9%) 62 (12%) 0.54
troke or TIA 0 9 (1.8%) 0.61
ypass surgery 10 (14%) 51 (10%) 0.32
mergent bypass surgery 4 (5.6%) 27 (5.4%) 1.00
mergent bypass surgery
due to failed PA
0 2 (0.4%) 1.00
leeding requiring
transfusion
6 (8%) 61 (12%) 0.35
ata are presented as the number (%) of patients. Patients might be included in more
han one complication category.bPA  primary angioplasty; TIA  transient ischemic attack.itals may be reluctant to transfer patients early in the throes
f AMI, unless they deteriorate clinically, at which time the
isk is much greater. Many patients may be too unstable on
rrival to be considered for transfer. Many tertiary centers
till do not offer PA as routine first-line care, even for their
wn patients with AMI, and thus may not have established
rotocols to perform immediate angioplasty on critically ill
atients who they accept in transfer. Even if all PCI centers
id provide PA as first-line therapy for AMI, the transfer of
ver-increasing numbers of patients with AMI and high-
isk acute coronary syndromes to tertiary centers could
uickly overload their capacity. Thus, the transfer approach
ill ultimately necessitate and depend on the development
f more interventional programs at more qualified commu-
ity hospitals in broader geographic locations.
All of these considerations support the need to expand
he availability of centers that are capable of offering PA
round the clock. The need for more interventional
acilities can be projected to increase even further in the
ear future, with the aging of the baby boomers and the
ncreasing application of PCI to more patient groups.
his increasing need for coronary intervention may well
utstrip the waning need for cardiac surgery facilities.
ncoupling angioplasty from the requirement for on-site
oronary bypass surgery will reduce the pressure to open
ore low-volume surgical programs to support needed
ew angioplasty programs (22).
The availability of qualified hospitals and operators
ho perform PA is limited in part by various local
equirements for on-site cardiac surgery. For example, at
east 11 states still have regulations prohibiting the use of
A at nonsurgical hospitals under any circumstances.
nvestigators from eight such states requested to partic-
pate in our registry but were not allowed to do so because
f these regulations.
The newly revised American College of Cardiology/
merican Heart Association guidelines for PCI (23) now
ccept PA at hospitals without on-site cardiac surgical
ackup, for which there is a “class IIb” indication (useful-
ess/efficacy less well established by evidence/opinion),
rovided that at least 36 PA procedures per year are
erformed at such hospitals, the interventionalist performs
t least 75 procedures per year, procedures are performed
ithin 90 30 min of arrival, and there is a proven plan for
apid access to a cardiac surgical center. These guidelines
lso include tables listing further operator, institutional, and
atient selection criteria for the performance of angioplasty
nd emergency coronary bypass surgery at such hospitals, as
riginally proposed by Wharton et al. (8).
There are over 800 community hospitals in the U.S. with
ardiac catheterization laboratories that do not have cardiac
urgery (7), many of which are staffed by experienced
nterventionalists. In view of the potential advantages of PA
nd the need to extend its availability to more patients in
roader geographic locations, the question of whether PA in
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The PAMI-No SOS Study June 2, 2004:1943–50he treatment of AMI can be performed safely and effec-
ively in primary care hospitals must be addressed.
The efficacy and safety of PA versus fibrinolytic therapy at
ospitals with off-site surgical backup was recently demon-
trated in the randomized Cardiovascular Patient Outcomes
esearch Team (C-PORT) trial (24). This 453-patient
tudy demonstrated the superiority of PA in reducing the
omposite end point of death, recurrent AMI, and stroke at
ix weeks and six months, compared with fibrinolytic
herapy at hospitals without cardiac surgery. The median
ength of stay was also reduced in the PA group. This trial
id not compare on-site PA at nonsurgical hospitals with
ransfer to tertiary cardiac surgical centers for PA.
A recent report from the NRMI investigators regarding
n-hospital mortality and times to reperfusion for PA in
igure 1. Comparison of lengths of stay and 30-day outcomes between pat
nd those treated with on-site PA at hospitals without cardiac surgery. The
reated with on-site PA. The graph on the right demonstrates a strong tr
o significant differences in recurrent myocardial infarction (reMI), disabli
ardiovascular events (MACE) at 30 days. Solid bars  patients transferre
onsurgical hospitals.
able 6. Multivariate Predictors of Mortality at One Year in the
ir PAMI-No SOS Study
Variables
Odds
Ratio 95% CI p Value
eart rate 100 beats/min 2.21 1.05–4.62 0.036
istory of hypertension 2.91 1.29–6.60 0.010
istory of COPD 3.62 1.07–12.2 0.038
illip class 1 3.43 1.64–7.15 0.001
o stent 2.59 1.17–5.72 0.019
nitial thrombus 4.90 1.41–17.0 0.012
andomized to transfer 1.10 0.37–3.31 0.86
I  confidence interval; COPD  chronic obstructive pulmonary disease; other
abbreviations as in Table 1.atients with ST-segment elevation AMI or left bundle
ranch block lends further support for PA at hospitals
ithout on-site cardiac surgery (25). Of 30,538 patients
reated with PA, 1,935 of these procedures were performed
t 97 hospitals without on-site cardiac surgery (of which 50
lso provide nonemergent angioplasty), with comparable
n-hospital mortality and shorter times to reperfusion for
ontransfer patients. The authors concluded that this
rompt treatment at nonsurgical hospitals, with no added
isk, was an alternative to transfer to hospitals with on-site
ardiac surgery and may have implications for national
ublic health.
he present study. This series represents the largest pro-
pective multicenter experience of PA in hospitals without
n-site cardiac surgery. Most previous reports of PA at
onsurgical hospitals represent the experiences of single
enters reporting their own outcomes (8,10–13). In this
tudy, all clinical outcomes were collected and adjudicated
y a single coordinating center, and all angiograms were
ubmitted for core laboratory analysis. This study demon-
trates that clinical outcomes in patients treated with PA at
ualified hospitals with off-site cardiac surgical backup are
imilar to outcomes of patients transferred to tertiary sur-
ical centers for PA, with more rapid reperfusion at the
onsurgical centers providing on-site PA.
tudy limitations. One possible criticism of the on-site PA
ata is that there could have been a selection bias. However,
transferred for primary angioplasty (PA) to tertiary cardiac surgical centers
on the left demonstrates a trend toward a shorter hospital stay in patients
ward lower mortality at 30 days in patients treated with on-site PA, but
rebrovascular accident (CVA), or the combination of these major adverse
ertiary centers for PA; striped bars  patients treated with on-site PA atients
graph
end to
ng ce
d to tll patients were enrolled prospectively if they met the
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June 2, 2004:1943–50 The PAMI-No SOS Studyelection criteria. A screening log was kept on all incoming
MI patients to address a potential selection bias. The
igher-than-expected incidence of anterior MI in the group
andomized to transfer may have been because it was easier
or the small primary care hospitals that were screening
atients for Air PAMI to select obvious patients (anterior
I) for randomization. The No-SOS sites were performing
rimary PCI in all patients as routine first-line care, with
ess likelihood of a selection bias.
Another limitation is that the patients in this series were
ot randomized. Although our experience demonstrates
utcomes that can be achieved at community hospitals
ithout cardiac surgery, this finding provides no indication
f whether alternative treatment with fibrinolytics or ran-
omization to transfer to a surgical center versus on-site PA
ight have led to similar outcomes. However, pooled data
rom 23 randomized studies of PA versus fibrinolytics has
lready demonstrated the superiority of angioplasty (1). It
ould seem that further randomized studies are unnecessary
o validate PA at centers without cardiac surgical programs
f such centers can demonstrate outcomes equivalent to
hose reported in these studies. This registry has demon-
trated such equivalence. In addition, randomization to
n-site PA versus fibrinolytics or transfer will reduce pro-
edural volumes at participating hospitals; thus, the ran-
omization process itself might adversely influence out-
omes by this dilutional effect on PA volumes.
The outcomes of our study may not be reproducible by
ther hospitals without cardiac surgical programs if they do
ot maintain the rigorous institutional, operator, laboratory,
nd procedural standards of this protocol, including ongo-
ng analysis of outcomes and case review. The outcomes of
A are very much dependent on operator expertise and
nstitutional commitment. We believe that cardiologists can
chieve results similar to ours at institutions that establish
rograms adopting rigorous standards such as those we
ropose (see Methods, under No SOS Registry Site Selec-
ion heading).
The decreased use of stents in patients transferred to
ertiary centers for PA, compared with the No SOS com-
unity hospitals, was unexpected. However, stenting has
nly been shown to reduce recurrent ischemia, but not
eath, re-infarction, or stroke (26,27), and thus the differ-
nce in stent use should not be expected to have influenced
he combined primary end point of our study. Also, because
tenting does not improve TIMI flow (26,27), the higher
ate of TIMI flow grade 3 in the No SOS group, as
djudicated by the core laboratory, cannot be attributed to
ncreased stent use.
Newer hospitals just beginning to offer PA raise partic-
lar concern that their inexperience may lead to suboptimal
utcomes. However, 49% of our study patients were en-
olled at sites just starting up new PA programs that could
eet our standards. The outcomes of these sites wereimilar to those of hospitals with more established pro-rams. The learning curves of these sites were not percep-
ible in their outcomes data.
Although we have demonstrated similar clinical outcomes
etween on-site PA and PA after transfer, as postulated, the
olume of patients in our transfer group is small. A larger
umber of patients in this group may have allowed the
rends we observed, favoring the on-site PA group to have
chieved statistical significance.
The surprisingly rapid enrollment of patients for on-site
A in the No SOS registry, compared with the much slower
nrollment in the Air PAMI study, suggests that on-site PA
s likely to become the preferred approach at qualified
ospitals without cardiac surgery.
onclusions. When prospectively compared with similar
atients transferred for PA, patients receiving on-site PA
ad more rapid reperfusion and similar 30-day outcomes.
rimary angioplasty in patients with high-risk AMI at
ospitals with off-site cardiac surgical backup is as safe and
ffective and significantly faster than PA after transfer to a
urgical facility.
Community hospitals wishing to establish successful PA
rograms must adopt rigorous standards for operators,
taffing, laboratories, equipment, and case selection and
aintain ongoing outcomes analysis and case review. Par-
icipation in the American College of Cardiology’s National
ardiovascular Data Registry should be strongly encour-
ged.
These results should not be understood to mean that PA
an or should be done at every hospital with cardiac
atheterization facilities. However, this report does suggest
hat the lack of cardiac surgery backup, per se, need not limit
he safety or efficacy of the broader application of this
ptimal treatment for patients with AMI.
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